ORIGINAL PAPER
Oral vs. subcutaneous low-dose methotrexate treatment in reducing gastrointestinal side effects
Online publication date: 2009-10-19
Reumatologia 2009;47(4):207-211
KEYWORDS
ABSTRACT
The aim of our present data was to compare the gastrological side effects of oral versus subcutaneous (SC) administration of methotrexate in patients with long-lasting rheumatoid arthritis (RA). We compared the intensity of gastrological side effects such as nausea, vomiting, loss of appetite, abdominal pain and diarrhea in patients who received methotrexate (MTX) in oral or subcutaneous doses of either 7.5 mg or 15 mg weekly. The survey research was used to evaluate the intensity of the above-mentioned side effects. The questionnaires were completed by a doctor, who conducted a structured interview with patients. Patients receiving oral MTX had more intense gastrological side effects. There was a correlation between dose of oral MTX and intensity of side effects. Patients receiving 15 mg MTX orally had significant severe vomiting and loss of appetite (p < 0.05). Nausea and loss of appetite turned out to be the most frequent side effects in patients receiving SC MTX 15 mg/weekly. In contrast to patients from the oral MTX groups none from the SC MTX groups exhibited vomiting or diarrhea. We found that SC MTX administration demonstrated a significant reduction of gastrological side effects’ intensity compared with oral administration of the same MTX dosage among patients with long-lasting RA. We also observed the possibility of dosage reduction of other DMARDs. Using SC MTX therapy allowed 50% oral dosage reduction in 14.6% of patients among patients who received them.
REFERENCES (13)
1.
Bingham SJ, Buch MH, Lindsay S, et al. Parenteral methotrexate should be given before biological therapy. Rheumatology (Oxford) 2003; 42: 1009-1010. .
2.
Felson DT, Anderson JJ, Meenan RF. Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials. Arthritis Rheum 1992; 35: 1117-1125. .
3.
Nagashima M, Matsuoka T, Saitoh K, et al. Treatment continuation rate in relation to efficacy and toxicity in long-term therapy with low-dose methotrexate, sulfasalazine, and bucillamine in 1,358 Japanese patients with rheumatoid arthritis. Clin Exp Rheumatol 2006; 24: 260-267 .
4.
Ferraccioli GF, Gremese E, Tomietto P, et al. Analysis of improvements, full responses, remission and toxicity in rheumatoid patients treated with step-up combination therapy (methotrexate, cyclosporin A, sulphasalazine) or monotherapy for three years. Rheumatology (Oxford) 2002; 41: 892-898. .
5.
Brooks PJ, Spruill WJ, Parish RC, Birchmore DA. Pharmacokinetics of methotrexate administered by intramuscular and subcutaneous injections in patients with rheumatoid arthritis. Arthritis Rheum 1990; 33: 91-94. .
6.
Johnston A, Gudjonsson JE, Sigmundsdottir H, et al. The antiinflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol 2005; 114: 154-163. .
7.
Braun J, Kaestner P, Flaxenberg P, et al. The clinical efficacy and safety of subcutaneous (s.c.) vs oral application of methotrexate (MTX) with patients with active rheumatoid arthritis (RA) – results of randomized, controlled, double-blind, multi-center study. Ann Rheum Dis 2006; 65 (suppl II): 87 .
8.
Brandt A. Results of an observational study with parenteral MTX. Medac GmbH Germany 2004. .
9.
Hoekstra M, van Ede AE, Haagsma CJ, et al. Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. Ann Rheum Dis 2003; 62: 423-426. .
10.
Kramer JM. Toward a better understanding of methotrexate. Arthritis Rheum 2004; 50: 1370-1382 .
11.
Braun J, Kästner P, Flaxenberg P, et al; MC-MTX.6/RH Study Group. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. .
12.
Wegrzyn J, Adeleine P, Miossec P. Better efficacy of methotrexate given by intramuscular injection than orally in patients with rheumatoid arthritis. Ann Rheum Dis 2004; 63: 1232-1234. .
13.
Świerkot J, Sokolik R, Gruszecka-Marczyńska K i wsp. Skuteczność leczenia i występowanie działań niepożądanych w trakcie terapii metotreksatem podawanym doustnie i pod - skór nie cho rym na reumatoidalne zapalenie stawów. Reu ma to - lo gia 2008; 46: 322-329.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
